Roche Holding AG Company Profile
Roche Holding AG
Pharmaceuticals
- Type
Public
- Headquarters
Switzerland
- Founded
1896
- Key Management
Mr.Severin Schwan(CEO)
- Revenue
~69,940.6(2021)
- Headcountz
~100,920(2021)
- Website
Business Description
Roche Holding AG, a research-based healthcare firm, is its name. Fritz Hoffmann-La Roche was the founder of the company, which was established on October 1, 1896. It is located in Basel, Switzerland. It is divided into two parts: Diagnostics and Pharmaceuticals. The Pharmaceutical division encompasses business segments like Roche Pharmaceuticals and Chuga. The Diagnostic division covers the following areas: centralized and direct care, tissue diagnostics, molecular diagnostics, and diabetic care.
Key Financials
Revenue (US$ Mn):
- US$ 69,941 Mn was Roche Holding AG’s annual revenue in 2021, an 8.41% increase from 2020 figures
- Roche Holding AG indexed a 4.9% increase in annual revenues from 2019, amounting to US$ 64,515 Mn in 2020
- Roche Holding AG generated total revenue of US$ 61,502 Mn in 2019
- Annual revenue of US$ 57,150 Mn was indexed by Microsoft Corporation in 2018
Operating Income (US$ Mn):
- US$ 19,283 Mn was the operating income generated by Roche Holding AG in 2021
- Roche Holding AG’s operating income for 2020 was US$ 20,512 Mn, a 16.82% increase from 2019
- From 2018’s operating incomes, Roche Holding AG registered an 18.46% increase in 2019, amounting to US$ 17,558 Mn
- An operating income of US$ 14,822 Mn was generated in 2018 by Roche Holding AG
Net Income (US$ Mn):
- Roche Holding AG’s net income for 2021 was US$ 15,863 Mn, a 0.32% increase from 2020
- The net income generated by Roche Holding AG in 2020 was US$ 15,813 Mn
- At a 27.93% increase, Roche Holding AG’s net income of US$ 13,505 Mn was indexed in 2019
- Roche Holding AG generated a net income of US$ 10,556 Mn in 2018
Operating Margin %:
- 28% was Roche Holding AG’s operating margin in 2021, a -13.52% decrease from 2020 figures
- Roche Holding AG indexed an 11.58% increase in operating margins from 2019, amounting to 32% in 2020
- Roche Holding AG generated an operating margin of 29% in 2019
- An operating margin of 26% was indexed by Microsoft Corporation in 2018
Gross Margin %:
- 23% was the gross margin generated by Roche Holding AG in 2021
- Roche Holding AG’s gross margin for 2020 was 25%, an 11.87% increase from 2019
- From 2018’s gross margins, Roche Holding AG registered a 19.02% increase in 2019, amounting to 22%
- A gross margin of 18% was generated in 2018 by Roche Holding AG
SWOT Analysis
Strength:
Strong R&D Capabilities Help Roche in Keeping its Product Pipeline Robust
Roche is a leader in research and development (R&D). Roche has 29 R&D centers that are focused on developing innovative solutions, diagnostic tools and services, and new drugs based on changing market trends. It also holds numerous patents in foreign and domestic countries and collaborates with academia, biotech start-ups, and spin-offs of small and large corporations, universities, and government laboratories around the world. Two research organizations within Roche, pRED (Roche Pharma Research and Early Development), and red(Genentech Research and Early Development) are responsible for developing new treatments for diseases with high unmet medical needs.
Roche’s R&D programs are focused on the areas of ophthalmology, immunology, and oncology. The company spent CHF12,152 million on R&D in FY2020. This accounted for 3.9% of the company’s total revenue. The company’s innovation-based strategies allow it to keep up with industry changes and provide it with a ‘first mover” advantage by launching products before the competition. It also provides advanced products and services for its customers.
Get this premium content
